Biogen projects confirmatory study for Alzheimer’s drug will take four years

Healthcare

Six months after Biogen was awarded regulatory approval for its Alzheimer’s disease drug Aduhelm, the company the company is laying out a timeline for the post-marketing study to confirm whether the drug works. The projected four-year study will enroll more than 1,300 patients and will include a placebo control arm.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.